Cantor Fitzgerald Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price

Nyxoah (NASDAQ:NYXH) had its price objective lowered by equities researchers at Cantor Fitzgerald to $3.00 in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price objective would suggest a potential upside of 218.47% from the stock’s previous close.

Several other research firms have also commented on NYXH. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nyxoah in a research report on Wednesday, August 19th. Piper Sandler reaffirmed an “overweight” rating and issued a $6.00 price target (down from $7.00) on shares of Nyxoah in a research note on Thursday, August 6th. Oppenheimer set a $4.00 target price on shares of Nyxoah in a research report on Thursday, August 6th. Robert W. Baird set a $2.31 target price on shares of Nyxoah in a research note on Thursday, August 6th. Finally, Wall Street Zen cut shares of Nyxoah from a “hold” rating to a “sell” rating in a research note on Sunday, August 9th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Nyxoah has an average rating of “Hold” and a consensus price target of $3.55.

Nyxoah Stock Up 3.4%

Shares of Nyxoah stock opened at $0.94 on Tuesday. The company’s fifty day simple moving average is $1.39 and its two-hundred day simple moving average is $2.58. The firm has a market cap of $36.51 million, a PE ratio of -0.37 and a beta of 1.65. Nyxoah has a 12-month low of $0.80 and a 12-month high of $5.92.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.20). The business had revenue of $8.76 million for the quarter, compared to analyst estimates of $8.64 million. As a group, sell-side analysts expect that Nyxoah will post -1.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NYXH. Integrated Wealth Concepts LLC purchased a new stake in Nyxoah in the 2nd quarter valued at about $169,000. IFP Advisors Inc raised its position in shares of Nyxoah by 35.6% during the 2nd quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock valued at $200,000 after acquiring an additional 31,061 shares in the last quarter. Finally, Readystate Asset Management LP bought a new position in Nyxoah during the 2nd quarter worth $351,000.

About Nyxoah

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.